Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Trends Endocrinol Metab. 2009 Jan;20(1):43-50. doi: 10.1016/j.tem.2008.09.003. Epub 2008 Nov 13.

Will GnRH antagonists improve prostate cancer treatment?

Author information

  • 1Department of Reproductive Biology, Imperial College London, Hammersmith Campus, Du Cane Road, London, W12 0NN, UK. ilpo.huhtaniemi@imperial.ac.uk

Abstract

Androgen ablation forms a basis for treating prostate cancer and is achieved either by surgical castration, or pharmacologically using oestrogens, anti-androgens and/or gonadotropin-releasing hormone (GnRH) analogues. GnRH antagonists (or blockers) offer a new means of treatment by directly blocking GnRH receptors. Advantages of GnRH antagonists include lack of the initial stimulation of gonadotropin and testosterone production, lack of gonadotropin microsurges and sustained follicle-stimulating hormone suppression; disadvantages include increased histamine release. This review discusses advantages and disadvantages of the GnRH antagonists currently in development, in light of receptor physiology and pre-clinical and clinical data. Comparative clinical trials will ultimately establish their efficacy in comparison to other pharmacotherapies. Therefore, continuing development and refinement is needed to improve prostate cancer treatment.

PMID:
19008119
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk